Literature DB >> 23636291

Targeting tumors using nanoparticle platforms: a phase I study of a systemically administered gene therapy system.

Christopher Larson1, Natalie Mendez, Tony Reid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23636291      PMCID： PMC3666643          DOI： 10.1038/mt.2013.76

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

1.  Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery.

Authors:  Liang Xu; Peter Frederik; Kathleen F Pirollo; Wen-Hua Tang; Antonina Rait; Lai-Man Xiang; Weiqun Huang; Idalia Cruz; Yuzhi Yin; Esther H Chang
Journal:  Hum Gene Ther       Date:  2002-02-10       Impact factor: 5.695

Review 2.  Precision-cut organ slices as a tool to study toxicity and metabolism of xenobiotics with special reference to non-hepatic tissues.

Authors:  R de Kanter; M Monshouwer; D K F Meijer; G M M Groothuis
Journal:  Curr Drug Metab       Date:  2002-02       Impact factor: 3.731

Review 3.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

4.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes.

Authors:  Liang Xu; Cheng-Cheng Huang; Weiqun Huang; Wen-Hua Tang; Antonina Rait; Yu Zhi Yin; Idalia Cruz; Lai-Man Xiang; Kathleen F Pirollo; Esther H Chang
Journal:  Mol Cancer Ther       Date:  2002-03       Impact factor: 6.261

5.  Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity.

Authors:  M Xu; D Kumar; S Srinivas; L J Detolla; S F Yu; S A Stass; A J Mixson
Journal:  Hum Gene Ther       Date:  1997-01-20       Impact factor: 5.695

Review 6.  Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy.

Authors:  L Xu; K F Pirollo; E H Chang
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

7.  The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers.

Authors:  M Hamada; T Fujiwara; A Hizuta; A Gochi; Y Naomoto; N Takakura; K Takahashi; J A Roth; N Tanaka; K Orita
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors.

Authors:  Neil Senzer; John Nemunaitis; Derek Nemunaitis; Cynthia Bedell; Gerald Edelman; Minal Barve; Robert Nunan; Kathleen F Pirollo; Antonina Rait; Esther H Chang
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

9.  Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide.

Authors:  Wei Yu; Kathleen F Pirollo; Bin Yu; Antonina Rait; Laiman Xiang; Weiqun Huang; Qi Zhou; Gözen Ertem; Esther H Chang
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

Review 10.  P53 abnormalities and outcomes in colorectal cancer: a systematic review.

Authors:  A J Munro; S Lain; D P Lane
Journal:  Br J Cancer       Date:  2005-02-14       Impact factor: 7.640
View more
  1 in total

Review 1.  Non viral vectors in gene therapy- an overview.

Authors:  Murali Ramamoorth; Aparna Narvekar
Journal:  J Clin Diagn Res       Date:  2015-01-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.